Literature DB >> 21856302

The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states.

Tim J Wigle1, Sarah K Knutson, Lei Jin, Kevin W Kuntz, Roy M Pollock, Victoria M Richon, Robert A Copeland, Margaret Porter Scott.   

Abstract

Mutations at tyrosine 641 (Y641F, Y641N, Y641S and Y641H) in the SET domain of EZH2 have been identified in patients with certain subtypes of non-Hodgkin lymphoma (NHL). These mutations were shown to change the substrate specificity of EZH2 for various methylation states of lysine 27 on histone H3 (H3K27). An additional mutation at EZH2 Y641 to cysteine (Y641C) was also found in one patient with NHL and in SKM-1 cells derived from a patient with myelodisplastic syndrome (MDS). The Y641C mutation has been reported to dramatically reduce enzymatic activity. Here, we demonstrate that while the Y641C mutation ablates enzymatic activity against unmethylated and monomethylated H3K27, it is superior to wild-type in catalyzing the formation of trimethylated H3K27 from the dimethylated precursor.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21856302     DOI: 10.1016/j.febslet.2011.08.018

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  37 in total

Review 1.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

Review 2.  Structure, mechanism, and regulation of polycomb-repressive complex 2.

Authors:  Lindsay E Moritz; Raymond C Trievel
Journal:  J Biol Chem       Date:  2017-09-14       Impact factor: 5.157

3.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

Authors:  Michael T McCabe; Heidi M Ott; Gopinath Ganji; Susan Korenchuk; Christine Thompson; Glenn S Van Aller; Yan Liu; Alan P Graves; Anthony Della Pietra; Elsie Diaz; Louis V LaFrance; Mark Mellinger; Celine Duquenne; Xinrong Tian; Ryan G Kruger; Charles F McHugh; Martin Brandt; William H Miller; Dashyant Dhanak; Sharad K Verma; Peter J Tummino; Caretha L Creasy
Journal:  Nature       Date:  2012-10-10       Impact factor: 49.962

4.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

Authors:  Sarah K Knutson; Tim J Wigle; Natalie M Warholic; Christopher J Sneeringer; Christina J Allain; Christine R Klaus; Joelle D Sacks; Alejandra Raimondi; Christina R Majer; Jeffrey Song; Margaret Porter Scott; Lei Jin; Jesse J Smith; Edward J Olhava; Richard Chesworth; Mikel P Moyer; Victoria M Richon; Robert A Copeland; Heike Keilhack; Roy M Pollock; Kevin W Kuntz
Journal:  Nat Chem Biol       Date:  2012-09-30       Impact factor: 15.040

Review 5.  Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention.

Authors:  Chen Shen; Christopher R Vakoc
Journal:  Curr Opin Oncol       Date:  2015-01       Impact factor: 3.645

6.  Citrullination/Methylation Crosstalk on Histone H3 Regulates ER-Target Gene Transcription.

Authors:  Kathleen W Clancy; Anna-Maria Russell; Venkataraman Subramanian; Hannah Nguyen; Yuewei Qian; Robert M Campbell; Paul R Thompson
Journal:  ACS Chem Biol       Date:  2017-05-09       Impact factor: 5.100

7.  Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2.

Authors:  Christopher G Nasveschuk; Alexandre Gagnon; Shivani Garapaty-Rao; Srividya Balasubramanian; Robert Campbell; Christina Lee; Feng Zhao; Louise Bergeron; Richard Cummings; Patrick Trojer; James E Audia; Brian K Albrecht; Jean-Christophe P Harmange
Journal:  ACS Med Chem Lett       Date:  2014-01-14       Impact factor: 4.345

8.  The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD).

Authors:  Olga F Sarmento; Phyllis A Svingen; Yuning Xiong; Zhifu Sun; Adebowale O Bamidele; Angela J Mathison; Thomas C Smyrk; Asha A Nair; Michelle M Gonzalez; Mary R Sagstetter; Saurabh Baheti; Dermot P B McGovern; Jessica J Friton; Konstantinos A Papadakis; Goel Gautam; Ramnik J Xavier; Raul A Urrutia; William A Faubion
Journal:  J Biol Chem       Date:  2016-12-01       Impact factor: 5.157

Review 9.  WEE1 tyrosine kinase, a novel epigenetic modifier.

Authors:  Kiran Mahajan; Nupam P Mahajan
Journal:  Trends Genet       Date:  2013-03-26       Impact factor: 11.639

Review 10.  Maintaining cell identity: PRC2-mediated regulation of transcription and cancer.

Authors:  Itys Comet; Eva M Riising; Benjamin Leblanc; Kristian Helin
Journal:  Nat Rev Cancer       Date:  2016-09-23       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.